Gleevec import price 13621079267 Leukemia targeted drug Gleevec purchasing agent

[Manufacturer] Indian Pharmaceuticals Limited [Trade name] Gleevec
[Common name] Imatinib mesylate
[Scientific name]
[English name] < .b< br/> [Specifications] Tablets/Bottles
[Validity Period] Months
[Storage] Store in a sealed container below ℃.

【Functional Treatment】
Gleevec is used to treat the chronic phase, accelerated phase or blast phase of Philadelphia chromosome-positive chronic myelogenous leukemia (+). The safety and effectiveness information for the treatment of adult patients with unresectable and/or metastatic malignant gastrointestinal stromal tumors () for the following indications mainly comes from foreign research data, with limited data in the Chinese population: - For the treatment of recurrent gastrointestinal stromal tumors in adults or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (+). -For the treatment of adult patients with hypereosinophilic syndrome(R) and/or chronic eosinophilic leukemia(R) with -R& fusion kinase. Imatinib mesylate is the world's first approved tumorigenesis-related signaling inhibitor for chronic myelogenous leukemia and gastrointestinal stromal tumors. Treatment should be initiated initially by a physician experienced in treating chronic myelogenous leukemia. The recommended dose of imatinib mesylate for patients in the blast phase and accelerated phase is /day, and for patients in the chronic phase who have failed interferon treatment, it is /day. Both are taken orally once a day. It is advisable to take the medicine with a meal and drink it once a day. A large glass of water and should be continued for as long as it is effective. If the blood picture permits and there are no serious adverse drug reactions, the dose may be considered to be increased from / day to / day, or from / day to / day (orally)
Starting dose: for acute myelogenous leukemia of chronic myelogenous leukemia For patients in chronic phase and accelerated phase, the recommended dose of imatinib mesylate is/day. For patients in chronic phase who have failed interferon therapy, and patients with malignant gastrointestinal stromal tumors that cannot be surgically removed or metastasized (), the recommended dose is It is taken orally once a day. It is recommended to take the medicine with a meal and drink a large glass of water. As long as it is effective, it should be taken continuously.
If the blood picture permits and there are no serious adverse drug reactions, the dose may be considered to be increased from / day to / day, or from / day to / day (taken in divided doses) under the following circumstances: disease progression, treatment of at least several After 1 month, satisfactory hematological response could not be obtained, and the hematological response that had been achieved disappeared again.
The dose must be adjusted in the following circumstances: If serious non-hematological adverse reactions (such as severe water retention) occur during treatment, the drug should be discontinued until the adverse reactions disappear, and then the dose will be adjusted according to the severity of the adverse reactions.
Adjustment of dosage in case of severe liver toxicity: If the increase in bilirubin exceeds the upper limit of the normal range or the increase in transaminase exceeds the upper limit of the normal range, the drug should be discontinued until the above indicators drop to the upper limit of the normal range respectively. Or . times or less.
Dose adjustment in neutropenia or thrombocytopenia: Acceleration or blast phase: If severe neutropenia and thrombocytopenia occur (neutrophils less than.&/or platelets less than&/recommended dose Reduce to / day. If blood cells continue to decrease for weeks, further reduce the dose to / day. If blood cells continue to decrease for weeks, it is advisable to discontinue the drug until neutrophils &.
&-Patients in the chronic phase after interferon treatment failure: it is advisable to discontinue the drug when the neutrophils are less than . To resume medication, the dose is /day. If neutrophils or platelets are reduced to the above values again, the dose is reduced to /day when medication is resumed.
Dosage for patients with liver failure: Methanesulfonate for patients with liver function impairment The plasma concentration of imatinib mesylate can increase, so these patients should be cautious when using this drug. There are no clinical data on the use of imatinib mesylate in patients with liver function impairment, and no recommendations for dosage adjustment can be made.
Dosage in Renal Failure and Elderly Patients: Creatinine clearance is known to decrease with age, while age has no significant effect on the pharmacokinetics of imatinib mesylate, as it has not been studied in patients with renal impairment. It has not undergone clinical trials, so it is impossible to make recommendations for dosage adjustments.